Evidence map›Paper›PMID 42806048›Full record

ArticleNature structural & molecular biology2026

HERC4-mediated ubiquitination licenses RIPK1 to initiate TNF-induced cell death.

Haohao Lu, Tongde Du, Lin Li, Dongmei Cao, Ke Li, Linjie Liu, Rui Li, Xiaoliang Yu, Shouqiao Hou, Xinhui Wang and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature structural & molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Haohao Lu *State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.ORCID http://orcid.org/0000-0002-7037-6279
Tongde Du *State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.
Lin LiProteomics Center, National Institute of Biological Sciences, Beijing, China.
Dongmei CaoState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.
Ke LiState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.
Linjie LiuSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Rui LiState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.
Xiaoliang YuState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.
Shouqiao HouState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.
Xinhui WangState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.
Minyan ShiState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.
Yanfen LiuSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Feng MaNational Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China.
She ChenProteomics Center, National Institute of Biological Sciences, Beijing, China. chenshe@nibs.ac.cn.ORCID http://orcid.org/0000-0002-0830-3263
Henning WalczakCell Death, Inflammation and Immunity Laboratory, CECAD Research Center and Institute of Biochemistry I (IBC1) of the Faculty of Medicine, University of Cologne, Cologne, Germany. h.walczak@uni-koeln.de.ORCID http://orcid.org/0000-0002-6312-4591
Sudan HeState Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China. hesd@ism.pumc.edu.cn.ORCID http://orcid.org/0000-0002-0846-1210

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TNF can activate both prosurvival and prodeath signaling downstream of tumor necrosis factor receptor 1 (TNFR1). Survival signaling originates from TNFR1-containing membrane-bound complex I, while death signaling is driven by cytosolic complex II. Receptor-interacting protein kinase 1 (RIPK1) is a central component of both complexes but the molecular switch converting RIPK1 from a prosurvival scaffold in complex I to a prodeath kinase in complex II has remained elusive. Here, we identify the E3 ligase HERC4 as the molecular determinant of prodeath signaling. We show that HERC4 binds complex I-derived S166-phosphorylated, kinase-active RIPK1 and ubiquitinates it within its death domain. This enables RIPK1 oligomerization and assembly of the apoptosis-inducing RIPK1-FADD-caspase 8-containing complex IIa and, upon caspase inhibition, formation of the necroptosis-initiating RIPK1-RIPK3-containing necrosome. HERC4 deficiency protects mice from TNF-induced systemic inflammatory response syndrome and acute liver injury. Thus, HERC4 is the link enabling complex I-derived RIPK1 to initiate death signaling.

Identifiers

PMID42806048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.